Brief: Timber Pharmaceuticals To Highlight Phase 2B Control Study Results In Multiple Presentations At 31St Eadv Congress
29/08/2022 13:04
Timber Pharmaceuticals Inc TMBR.A :
* TIMBER PHARMACEUTICALS TO HIGHLIGHT PHASE 2B CONTROL STUDY
RESULTS IN MULTIPLE PRESENTATIONS AT 31ST EADV CONGRESS
Source text for Eikon: ID:nGNX7HyqKg
Further company coverage: TMBR.A
Recent news on Trex Wind-Down
See all newsBrief: NYSE American To Suspend Trading Immediately In Timber Pharma
Brief: Timber Pharmaceuticals Receives Court Approval Of All “First Day” Motions To Support Business
Brief: NYSE American to Commence Delisting Proceedings Against Timber Pharmaceuticals
Brief: Timber Pharmaceuticals Says Prior To Filing Of Chapter 11 Case, Debtors Entered Into A "Stalking Horse" Asset Purchase Agreement
Brief: Timber Pharmaceuticals Inc Files For Voluntary Chapter 11 Bankruptcy - Court Filing